Secondary ocular hypertension as an adverse effect of treatment with intravitreal dexamethasone implant: A retrospective Swedish cohort study
Our finding that 30.5% of eyes received IOP-lowering treatment confirms that SOHT is a prevalent complication following intravitreal dexamethasone implants. Male gender and higher baseline IOP were key indicators for developing SOHT after Ozurdex® treatment, emphasizing the need for vigilant monitoring. Most cases were managed with IOP-lowering eye drops, indicating that while common, SOHT is typically manageable without invasive interventions.
Authors
- Sanaa M. Kamal (ORCID: https://orcid.org/0000-0002-2052-7956)
- Abbas Al‐Hawasi (ORCID: https://orcid.org/0000-0002-8534-080X)
- Marita Andersson Grönlund (ORCID: https://orcid.org/0000-0002-6298-360X)
- Madeleine Zetterberg (ORCID: https://orcid.org/0000-0001-8230-0741)
- Martin Breimer
- Imadeddin Abu Ishkheidem
Institutions
- Uppsala University (SE)
- Örebro University (SE)
- Sahlgrenska University Hospital (SE)
- Region Västra Götaland (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Acta Ophthalmologica
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1111/aos.17475
- Citations
- 2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.41